HCPCS Level II code S3852 denotes DNA analysis for the APOE epsilon 4 allele to assess susceptibility to Alzheimer’s disease. This molecular diagnostic identifies presence of the APOE ε4 allele, which is associated with increased risk of late-onset Alzheimer’s and can inform clinical discussions on risk stratification and genetic counseling. Nationally, availability and coverage of APOE testing affects access to genetic risk information and downstream clinical services.

Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, expected sites of service (clinical laboratories and outpatient genetic testing facilities), and payer context. The publication provides benchmarks and policy summaries where available, clarifies coding and billing considerations tied to this HCPCS Level II code, and outlines clinical context relevant to ordering clinicians and billing staff.

The summary highlights implications for utilization management, preauthorization practices, and the role of genetic counseling when reporting susceptibility testing. Data not available in the input are identified where applicable, and the piece is intended as a national overview of code S3852 for stakeholders involved in molecular diagnostics, billing, and policy.